00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Lilly licenses Aduoro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
00:04 , Dec 21, 2018 |  BC Extra  |  Preclinical News

STING inhibitors could treat NASH

A paper in this week's edition of The Journal of Clinical Investigation expands the list of indications that could be treated by targeting the STING pathway, suggesting that inhibiting the cytosolic DNA sensor could help...
02:11 , Dec 19, 2018 |  BC Extra  |  Company News

Lilly licenses Aduro’s STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
22:10 , Nov 7, 2018 |  BC Extra  |  Preclinical News

GSK’s systemic STING agonist could overcome delivery hurdles

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have spread. At...
13:02 , Nov 6, 2018 |  BC Extra  |  Preclinical News

Codiak’s exosomes could offer new tack to STING agonism

Exosome company Codiak BioSciences Inc. (Cambridge, Mass.) on Tuesday provided a first glimpse of preclinical data for its exoSTING program, with a therapy that is among the next generation of STING agonists that go beyond...
16:47 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck...
01:10 , Oct 22, 2018 |  BC Extra  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. This...